Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that the National Comprehensive Cancer Network® (NCCN®) has updated its Clinical Practice ...
The U.S. Breast Cancer Liquid Biopsy Market is projected to grow from USD 0.39 Billion in 2025 to USD 0.84 Billion by 2035, ...
Medical Device Network on MSN
Quest Diagnostics’ Haystack MRD test secures NYSDOH approval
The clearance gives New York clinicians access to the Haystack MRD assay, which detects residual or recurring solid tumour ...
Concurrent circulating tumor DNA and tissue-based testing identified more patients eligible for personalized cancer care than either of the tests done alone. There are two popular testing strategies ...
Serial circulating tumor DNA (ctDNA) testing showed limited clinical benefit in colorectal cancer (CRC) surveillance when frequent imaging is used. The study's retrospective design and small sample ...
With an FDA approval for its companion diagnostic in bladder cancer, Natera extends its Treatment on MRD strategy, deferring ...
Natera Inc. NTRA stock is up Tuesday as the company celebrates a significant milestone with the National Comprehensive Cancer ...
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the publication of a new study in npj Precision Oncology ...
Dr. Alan Tan explores circulating tumor DNA, its role in clinical trials and its potential impact on patients with renal cell carcinoma. Circulating tumor DNA (ctDNA) is not yet standard practice in ...
The ZEST clinical trial, designed to evaluate niraparib (Zejula) for the prevention of breast cancer recurrence in patients with circulating tumor DNA (ctDNA), failed to accrue enough patients ...
For years, breast cancer treatment has been guided by genetic alterations found in tumor tissue, typically through invasive biopsies. However, the dynamic nature of cancer and limitations in tissue ...
A data analysis from a randomized clinical trial for stage 3 colon cancer patients by investigators at Dana-Farber Brigham Cancer Center found that patients with evidence of residual cancer in their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results